Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team

To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatrics (Evanston) 1999-09, Vol.104 (3), p.e32-e32
Hauptverfasser:	Raskino, C, Pearson, D A, Baker, C J, Lifschitz, M H, O'Donnell, K, Mintz, M, Nozyce, M, Brouwers, P, McKinney, R E, Jimenez, E, Englund, J A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent AIDS/HIV Analysis of Variance Anti-HIV Agents - therapeutic use Brain - growth & development Central Nervous System Diseases - etiology Central Nervous System Diseases - prevention & control Child Child, Preschool Cognition - drug effects Didanosine - therapeutic use Double-Blind Method Drug Therapy, Combination Female HIV Infections - complications HIV Infections - drug therapy Humans Infant Intelligence Tests Male Motor Skills - drug effects Pediatrics Reverse Transcriptase Inhibitors - therapeutic use Zidovudine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children. Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to
ISSN:	0031-4005 1098-4275
DOI:	10.1542/peds.104.3.e32